Piramal Pharma Limited Announces Consolidated Results for Q1FY25
Consolidated Financial Highlights |
|||
(in ₹ Cr. or as stated) |
|||
Particulars |
Q1FY25 |
Q1FY24 |
YoY Growth |
Revenue from Operations |
1,951 |
1,749 |
12 % |
CDMO |
1,057 |
898 |
18 % |
Complex Hospital Generic (CHG) |
631 |
617 |
2 % |
|
264 |
239 |
10 % |
EBITDA |
224 |
171 |
31 % |
EBITDA Margin |
11 % |
10 % |
|
PAT |
(89) |
(99) |
NA |
PAT Margin |
(5 %) |
(6 %) |
NA |
Key Highlights for Q1FY25
- Revenue from Operations grew by 12% YoY in Q1FY25, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the ICH business
- EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24, driven by operating leverage, cost optimization measures and superior revenue mix
- Best-in-class quality track record - Successfully closed the
USFDA inspections at Lexington facility (US) with an EIR# and atPPDS facility (Analytical Services,India ) with zero observations -
Piramal Pharma was honoured as one of the top Sustainable Organizations at the 3rd edition of 'Times Now Global Sustainability Alliance Sustainable Organizations 2024'
"As a responsible organisation, we are taking good strides in our journey towards building sustainable operations. Our continuous efforts in quality and compliance bore fruits with successful closure of
"Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25. We intend to further build on to the good start that we have had to the financial year."
Key Business Highlights for Q1FY25 |
Complex Hospital Generics (CHG):
|
Consolidated Profit and Loss Statement |
|||
(in ₹ Cr. or as stated) |
|||
Reported Financials |
|||
Particulars |
Q1FY25 |
Q1FY24 |
YoY Change |
Revenue from Operations |
1,951 |
1,749 |
12 % |
Other Income |
20 |
38 |
(49) % |
Total Income |
1,971 |
1,787 |
10 % |
Material Cost |
674 |
627 |
8 % |
Employee Expenses |
580 |
496 |
17 % |
Other Expenses |
493 |
494 |
0 % |
EBITDA |
224 |
171 |
31 % |
Finance Cost |
107 |
119 |
(10) % |
Depreciation |
185 |
174 |
6 % |
Share of Net Profit of Associates |
22 |
14 |
56 % |
Profit Before Tax |
(45) |
(107) |
NA |
Tax |
44 |
(9) |
NA |
Net Profit after Tax |
(89) |
(99) |
NA |
Exceptional Items |
0 |
0 |
NA |
Net Profit after Tax after Exceptional Items |
(89) |
(99) |
NA |
Q1FY25 Earnings Conference Call
The dial-in details for the call are as under:
Event |
Location & Time |
Telephone Number |
Conference call on |
|
+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
1 800 120 1221 (Toll free number) |
||
(Eastern Time – |
Toll free number 18667462133 |
|
(London Time) |
Toll free number 08081011573 |
|
(Singapore Time) |
Toll free number 8001012045 |
|
(Hong Kong Time) |
Toll free number 800964448 |
|
Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6099661&linkSecurityString=26cd0b7825 |
About
For more information, visit:
# EIR - Establishment Inspection Report
* Includes one facility via PPL's minority investment in Yapan Bio.
Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy25-302207448.html
SOURCE